Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | APEX1 | P27695 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.96 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.77 |
| ▸ | GLA | P06280 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.65 |
| ▸ | TUBB | P07437 | 3/20 | 0.65 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.65 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.65 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.65 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.65 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351790 | 1.00 | TSHR (1.00) | TSHRCYP1A2CYP3A4NFKB1LMNA | |
| Hydrochloric Acid SCHEMBL1299364 | 0.98 | LMNA (1.00) | TSHRCYP1A2CYP3A4NFKB1LMNA | |
| SCHEMBL28994052 | 0.95 | TSHR (0.90) | TSHRCYP1A2CYP3A4NFKB1LMNA | |
| SCHEMBL68386 | 0.87 | TAAR1 (1.00) | TSHRCYP1A2CYP3A4NFKB1LMNA | |
| SCHEMBL29365033 | 0.87 | TAAR1 (1.00) | TSHRCYP1A2CYP3A4NFKB1LMNA | |
| SCHEMBL9827407 | 0.86 | TSHR (0.75) | TSHRCYP1A2CYP3A4NFKB1LMNA | |
| Dopamine SCHEMBL27902229 | 0.86 | TAAR1 (0.90) | TSHRCYP1A2CYP3A4NFKB1LMNA | |
| SCHEMBL30873093 | 0.85 | TUBB4A (0.75) | TSHRCYP1A2CYP3A4NFKB1LMNA | |
| Hydrochloric Acid SCHEMBL347598 | 0.85 | TAAR1 (1.00) | TSHRCYP1A2CYP3A4NFKB1LMNA | |
| SCHEMBL27183302 | 0.85 | TUBB4A (0.75) | TSHRCYP1A2CYP3A4NFKB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-10 | — | — | US | claimed |
| CN-118879199-A | Method for preparing anti-adhesion nano coating based on molecular brush grafting technology | 大连理工大学 | 2024-11-01 | — | — | CN | claimed |
| CN-118878830-A | Phenol-terminated organosilicon polymer and preparation method thereof | 大连理工大学 | 2024-11-01 | — | — | CN | claimed |
| US-12122784-B2 | Preparation method for ecteinascidin compound and intermediate thereof | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-10-22 | — | — | US | claimed |
| WO-2024183010-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | 中国科学院过程工程研究所 | 2024-09-12 | — | — | WO | claimed |
| US-20240294549-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TRABECTEDIN | NATCO PHARMA LIMITED (IN) | 2024-09-05 | — | — | US | claimed |
| WO-2024126555-A1 | USE OF ONE OR MORE PARTICULAR ALKYLAMINE COMPOUNDS FOR THE COSMETIC TREATMENT OF KERATIN FIBRES | L'OREAL (FR) | 2024-06-20 | — | — | WO | claimed |
| CN-117479964-A | Tissue-selective single-component mRNA delivery vector and delivery system | 中国科学院过程工程研究所 | 2024-01-30 | — | — | CN | claimed |
| EP-3842438-B1 | PREPARATION METHOD FOR ECTEINASCIDIN COMPOUND AND INTERMEDIATE THEREOF | BRIGHTGENE BIO MEDICAL TECH CO LTD (CN) | 2023-11-08 | — | — | EP | claimed |
| CN-111518110-B | Preparation method of ecteinascidin compound and intermediate thereof | 博瑞生物医药（苏州）股份有限公司 | 2023-11-03 | — | — | CN | claimed |
| US-20120016390-A1 | BIOADHESIVE COMPOUNDS AND METHODS OF SYNTHESIS AND USE | KNC NER ACQUISITION SUB, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-20090171080-A1 | Intermediate and Process of Preparation of Ecteinascidin Such as Ecteinascidines-583,597 Using Such Intermediate | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-07-02 | — | — | US | claimed |
| EP-1937689-A2 | INTERMEDIATE AND PROCESS OF PREPARATION OF ECTEINASCIDIN SUCH AS ECTEINASCIDINES-583, 597 USING SUCH INTERMEDIATE | Centre National de la Recherche Scientifique (FR) | 2008-07-02 | — | — | EP | claimed |
| EP-1792904-A1 | Intermediate and process of preparation of ecteinascidin using such intermediate | Centre National de la Recherche Scientifique (CNRS) (FR) | 2007-06-06 | — | — | EP | claimed |
| WO-2007045686-A2 | INTERMEDIATE AND PROCESS OF PREPARATION OF ECTEINASCIDIN SUCH AS ECTEINASCIDINES-583, 597 USING SUCH INTERMEDIATE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-04-26 | — | — | WO | claimed |
| EP-0931083-B1 | PROCESS FOR PRODUCING ECTEINASCIDIN COMPOUNDS | HARVARD COLLEGE (US) | 2003-02-19 | — | — | EP | claimed |
| EP-0931083-A4 | PROCESS FOR PRODUCING ECTEINASCIDIN COMPOUNDS | HARVARD COLLEGE (US) | 2000-05-24 | — | — | EP | claimed |
| EP-0931083-A1 | PROCESS FOR PRODUCING ECTEINASCIDIN COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1998012198-A1 | PROCESS FOR PRODUCING ECTEINASCIDIN COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-03-26 | — | — | WO | claimed |
| US-5721362-A | Process for producing ecteinascidin compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | SLC43A1, LNPEP, TLR3 | TSHR 3014/4885CYP1A2 3755/4885CYP3A4 3631/4885 |
| US-20240294549-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TRABECTEDIN | BMP4, TYMP, TYMS | TSHR 2236/4885CYP1A2 455/4885CYP3A4 128/4885 |
| US-20090171080-A1 | Intermediate and Process of Preparation of Ecteinascidin Such as Ecteinascidines-583,597 Using Such Intermediate | MMP7, CCR7, AREG | TSHR 673/4885CYP1A2 927/4885CYP3A4 2123/4885 |
| US-12122784-B2 | Preparation method for ecteinascidin compound and intermediate thereof | TMED9, EMD, ENTPD8 | TSHR 2612/4885CYP1A2 551/4885CYP3A4 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.